lewis-x-antigen and Pheochromocytoma

lewis-x-antigen has been researched along with Pheochromocytoma* in 2 studies

Other Studies

2 other study(ies) available for lewis-x-antigen and Pheochromocytoma

ArticleYear
Leu-M1 immunoreactivity and phaeochromocytoma.
    Journal of clinical pathology, 1997, Volume: 50, Issue:2

    The aim was to evaluate Leu-M1 immunoreactivity as a prognostic factor in phaeochromocytoma. Anti-Leu-M1 monoclonal antibodies were used to determine the Leu-M1 immunoreactivity in 17 histologically confirmed phaeochromocytomas from 15 patients, using an avidin-biotin technique. Ten patients had a sporadic phaeochromocytoma, and five had multiple endocrine neoplasia type 2A (MEN 2A). Malignancy was diagnosed in three patients by the presence of metastases. Leu-M1 immunoreactivity was shown in 12 (70.5%) phaeochromocytomas. Three patterns of arrangement were observed: isolated (scattered positive cells) (n = 3); focal (aggregates of positive cells) (n = 5), and diffuse patterns (dispersed positive cells) (n = 4). Two cases of malignant phaeochromocytoma were positive (one focal and one isolated pattern). All cases of MEN 2A showed immunoreactivity, although no characteristic pattern was prevalent. A diffuse pattern was observed in all phaeochromocytomas longer than 7 cm. In conclusion, Leu-M1 expression is frequent in phaeochromocytoma. However, Leu-M1 immunoreactivity seems to be useless in predicting malignant behaviour and to be influenced mainly by tumour size.

    Topics: Adrenal Gland Neoplasms; Adult; Aged; Female; Humans; Immunohistochemistry; Lewis X Antigen; Male; Middle Aged; Multiple Endocrine Neoplasia Type 2a; Pheochromocytoma; Prognosis

1997
Induction of NILE/L1 glycoprotein during neuronal differentiation of the embryonal carcinoma cell line EC1003.
    Differentiation; research in biological diversity, 1991, Volume: 46, Issue:3

    A new clone of the mouse embryonal carcinoma cell line 1003 (EC 1003.16) can be maintained in an undifferentiated state in serum-containing medium. Shifting these cells to serum-free, hormonally defined medium causes them to differentiate morphologically and acquire a number of molecular properties characteristic of neurons. Whereas undifferentiated cells lack the NILE/L1 glycoprotein, expression of this neuronal cell adhesion molecule is induced in the differentiating cells. Message for NILE/L1 becomes detectable after 5 days in serum-free medium, and cell-surface NILE/L1 can first be seen at this same time. Changes in two other cell adhesion molecules occur in parallel with the induction of NILE/L1. Fibronectin receptor is present on undifferentiated cells, but is down-regulated by the differentiating neurons. The neural cell adhesion molecule (N-CAM) undergoes a shift from the very adhesive adult form to the less adhesive, highly sialylated embryonic form. These changes would appear to emphasize the role of NILE/L1 in adhesive interactions involving differentiating neurons. Some changes in ganglioside expression also occur during EC 1003.16 differentiation. Undifferentiated cells express the D 1.1 ganglioside but lack gangliosides that are reactive with the monoclonal antibody A2B5. Differentiating cells lose D 1.1 and become A2B5-positive. Since D 1.1 is characteristic of undifferentiated neuroepithelial cells and A2B5 reactivity is a marker for several types of differentiated neurons, these changes in vitro appear to mimic events that occur in vivo.

    Topics: Adrenal Gland Neoplasms; Animals; Biomarkers; Blotting, Northern; Cell Adhesion Molecules, Neuronal; Cell Differentiation; Down-Regulation; Fluorescent Antibody Technique; Gene Expression; In Vitro Techniques; Lewis X Antigen; Membrane Glycoproteins; Mice; Neoplasms, Germ Cell and Embryonal; Neural Cell Adhesion Molecule L1; Neurons; Pheochromocytoma; Rats; Receptors, Fibronectin; Receptors, Immunologic; RNA; Tretinoin; Tumor Cells, Cultured; Vimentin

1991